An interpretation of the new international MAP guideline for the management of Milk Allergy in Primary Care by Netts P & Michaelis LJ
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This work is licensed under a Creative Commons Attribution 4.0 International License 
 
 
Newcastle University ePrints - eprint.ncl.ac.uk 
 
Netts P, Michaelis LJ.  
An interpretation of the new international MAP guideline for the 
management of Milk Allergy in Primary Care.  
Clinical and Translational Allergy 2017, 7, 34. 
 
Copyright: 
© The Author(s) 2017. This article is distributed under the terms of the Creative Commons Attribution 4.0 
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, 
distribution, and reproduction in any medium, provided you give appropriate credit to the original 
author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were 
made. The Creative Commons Public Domain Dedication waiver 
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, 
unless otherwise stated 
DOI link to article: 
https://doi.org/10.1186/s13601-017-0171-x  
Date deposited:   
11/10/2017 
Netts and Michaelis  Clin Transl Allergy  (2017) 7:34 
DOI 10.1186/s13601-017-0171-x
EDITORIAL
An interpretation of the new 
international MAP guideline for the 
management of Milk Allergy in Primary Care
Paul Netts1 and Louise J. Michaelis2,3*
Abstract 
General Practitioners suffer from guideline fatigue. They come fast and furious in many complicated forms. Cow’s milk 
allergy (CMA) is one of the most common presentations of food allergy seen in early childhood presenting to primary 
and secondary care. The early and accurate diagnosis continues to be highlighted in many countries worldwide. 
International surveys have found that primary care clinicians would like clearer explanations for the options for the 
diagnosis of CMA and in so doing a means to increase their understanding of management options for both IgE and 
Non IgE mediated CMA. In 2013 in response to General Practitioner demands, the UK guideline, ‘Diagnosis and man-
agement of non-IgE-mediated CMA in infancy—a UK primary care practical guide’ was published in this journal. This 
Milk Allergy in Primary Care (MAP) guideline outlines in simple algorithmic form how to diagnose, manage and refer 
children with CMA in a primary care setting. Based on the international uptake of the MAP guideline, a global practical 
guideline International MAP is presented by the Venter and Brown et al to help practitioners in primary care settings. 
It incorporates further published UK guidance, feedback from UK healthcare professionals and affected families and, 
importantly, also international guidance and expertise.
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Primary care has guideline fatigue. The sheer number 
and rate with which they appear is challenging and cur-
rently General Practitioners (GPs) in the United King-
dom (UK) do not follow the vast majority of them at 
the best of times [1]. This is of particular concern as, in 
many respects, GPs and other community clinicians are 
increasingly bound by them in three important ways 
(a) clinically, where they offer an easy way of maintain-
ing up-to-date care, (b) legally, where they often define 
acceptable practice, and (c) ethically, given their impact 
on practitioner autonomy, patient empowerment, stand-
ardisation of care and management of costs [2].
Given this current climate, how can a guideline about 
the management of IgE and Non IgE mediated cow’s milk 
allergy (CMA) in primary care in the UK begin to have 
an impact? After all, primary care, in the case of non-IgE 
CMA, is being asked to manage a condition that has no 
current diagnostic test, seems self-limiting and, through 
the eyes of the uninitiated, does not appear to result in 
detrimental effects on future health for children if left 
unrecognised and untreated. Add to this a lingering 
opposition to the very existence of non-IgE CMA as a 
clinical entity, both in primary and secondary care, and 
the challenge seems even greater. Yet despite all this, the 
original “Milk Allergy in Primary Care (MAP)” UK guide-
line [3], which was originally launched in 2013, has been 
well received and is being successfully implemented glob-
ally [4]. This is particularly evident when it is presented 
with a clear algorithm and a simple accompanying train-
ing package for both breast and formula fed infants.
For a guideline to produce such a change in behavior 
suggests that it is imparting new knowledge on those that 
read and use it [5]. This prior lack of knowledge in UK 
primary care, along with an associated lack of confidence 
Open Access
Clinical and
Translational Allergy
*Correspondence:  Louise.michaelis@nuth.nhs.uk 
2 Department of Paediatric Allergy, Great North Children’s Hospital, 
Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon 
Tyne NE1 4LP, UK
Full list of author information is available at the end of the article
Page 2 of 3Netts and Michaelis  Clin Transl Allergy  (2017) 7:34 
in managing food allergy, had been highlighted years 
earlier [6]. These deficiencies manifested themselves 
with delays in diagnosis, multiple unnecessary appoint-
ments and significant inappropriate prescribing of for-
mula milks. To further compound the situation there 
was limited knowledge about the types of formula milks 
available, a dearth of dietetic support as well as a strik-
ing disconnect between primary and secondary care with 
many patients turning to tertiary care for assistance.
The 2003 Royal College of Physicians (UK) report, 
“Allergy the unmet need: a blueprint for better patient 
care” called for the development of “co-ordinated allergy 
services delivered seamlessly by primary and second-
ary care”. It was envisaged that ultimately these services 
would be led by primary care so education and guidance 
was clearly required [7, 8]. Fortunately the evidence at 
the time was that the appetite for such training existed 
and that targeted education was effective in increasing 
confidence amongst GPs [9]. In 2010 the World Allergy 
Organization (WAO) Diagnosis and Rationale for Action 
against Cow’s Milk Allergy (DRACMA) guideline [10] fur-
ther clarified the diagnosis, treatment and subsequent 
prognosis of CMA and gave advice for every presentation 
from suspicion to anaphylaxis.
In 2011 the National Institute of Health and Care 
Excellence (NICE) UK guidance [11] asserted that pri-
mary care needed a guideline to manage CMA but fell 
short of informing GPs what to do, let alone provide the 
treatment algorithm they sought. Two years later the 
MAP guideline was published which did exactly that [3]. 
It originated from separate infant feeding programmes 
in Northern Ireland before developing into a national 
UK guideline. It provided the first treatment algorithm 
and pathway of care for CMA with the focus on non-IgE 
CMA (given its potential for management solely in pri-
mary care). Included in this pathway was visual instruc-
tion that allowed for formal diagnosis of non-IgE CMA 
not previously offered by the UK NICE guidance.
To address a clinical need however is not enough by 
itself to ensure the quality of any guideline; this requires 
that the development process be robust by ensuring clar-
ity, applicability, involvement of all stakeholders and a 
strong evidence base [8]. The MAP guideline met these 
criteria and, as 60,000 downloads (personal communica-
tion) worldwide will attest to, remains extremely popular 
despite a strong UK focus. The new iMAP guideline how-
ever, has identified that a more international approach is 
needed and has gained an “i” in recognition of this [12]. 
Whilst the UK has the highest prevalence of non-IgE 
CMA in Europe [13] and prescribes more amino acid 
formula milk as first choice than anywhere else in Europe 
the problem is certainly not confined to British shores 
[14]. Changes have therefore been made that are sensitive 
to the needs of other countries.
The general layout of the new iMAP guideline and the 
focus on non-IgE CMA remains unchanged; however the 
alterations that have been made aim to improve the ease 
and efficacy of everyday food allergy management. One 
of the ways in which it seeks to do this is by aiding the 
process of making an accurate and timely diagnosis [11]. 
The importance of the early recognition of food allergy in 
the first 1000 days of a child’s life has been shown to be 
crucial [15]. Emphasis is now placed on the need for an 
appropriate allergy focussed history and physical exami-
nation by a clinician at first contact. In the non-IgE sec-
tion there is a more detailed list of possible presenting 
symptoms. Clearer instruction, in the form of a written 
protocol, for both parent and health care professional 
alike, outlines the withdrawal and subsequent home re-
introduction of cow’s milk that is necessary to confirm 
or refute the diagnosis. Further helpful documentation is 
provided: an initial factsheet for parents, an amended less 
intense milk ladder and a sheet of useful recipes.
The iMAP guideline further supports the vital role of 
the community dietitian in every child with a food allergy. 
Dietitians in the UK bring their own expertise to the 
platform; promoting the importance of breast feeding, 
monitoring of growth, supervising vitamin and calcium 
supplementation for both mother and child, maintaining 
an understanding of the different types of formula milks 
and providing a gateway to food inclusion rather than 
exclusion. Home re-introduction (double blind placebo 
controlled in the Netherlands guideline) is vital if CMA 
is refuted and the dietitian is crucial in supporting this 
outcome.
The challenge remains however to ensure that primary 
care is educated enough to recognise that an array of 
symptoms and conditions, that can stand alone as clinical 
entities in and of themselves, may in fact be the presenta-
tion of allergy. A survey in 2015 demonstrated that only a 
third of GPs felt equipped to deal with food allergy [16]. 
It is essential that clinicians are aware that appropriate 
early treatment could halt or minimise the likelihood of 
these children developing other co-morbid allergic con-
ditions such as atopic dermatitis, asthma and allergic rhi-
nitis [17]. Such quality management could save everyone 
time and resources [6] as well as potentially reducing the 
incidence and prevalence of these increasingly burden-
some conditions. There is a clinical imperative to manage 
in this way as in the UK alone atopic disease has trebled 
in the last 20  years, with 13 million people below their 
mid-forties having two or more allergies [7].
In conclusion, the iMAP Guideline, is an evidence 
based, practical clinical algorithm that will further 
enhance the ability of health care professionals in 
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primary care to better recognise and manage CMA. They 
can be used as the foundation for the training and edu-
cation that will ultimately result in a primary care that is 
more confident and better placed to receive and imple-
ment the next advances in allergy management. The use 
of probiotics in breast fed babies, synbiotics in formula 
milks [18–20], food desensitisation [21] and the induc-
tion of oral tolerance will represent the next management 
challenges for primary care. All this makes seamless col-
laboration with secondary and tertiary services, along 
with strong dietetic and strong community nursing com-
munity support (e.g. in the UK health visitor support), all 
the more important. Improved patient care and safety, 
with a reduction in overall health costs be they social, 
emotional and/or financial, will be evident. By sowing 
the seeds of early recognition and diagnosis, and follow-
ing this with evidence based management, patients and 
clinicians alike will reap the benefits both now and in the 
future. The iMAP guideline will play no small part in con-
tributing to this.
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